BioPharmSignal logoBioPharmSignal

Biotech News

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bluejay Diagnostics (BJDX)Bluejay DiagnosticsFinancing

$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash, it is

Related news

BJDXBluejay Diagnostics2026-06-06 00:13 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2025-10-10 21:16 EST

Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

INBSIntelligent Bio Solutions2026-01-02 22:00 EST

Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

INBSIntelligent Bio Solutions2025-12-31 22:20 EST

Intelligent Bio Solutions Announces $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

VRAXVirax Biolabs2025-12-04 21:05 EST

Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

VRAXVirax Biolabs2025-12-03 18:53 EST

Virax Biolabs Group Limited Announces $5 Million Private Placement

LUCDLucid Diagnostics2026-04-24 14:23 EST

Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock

LUCDLucid Diagnostics2026-04-23 12:30 EST

Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock

BIAFbioAffinity Technologies, Inc.2026-06-17 13:25 EST

bioAffinity Technologies Announces Pricing of $3.2 Million Offering

BIAFbioAffinity Technologies, Inc.2026-06-18 17:16 EST

bioAffinity Technologies Announces Closing of $3.2 Million Offering

View all latest news

Bluejay Diagnostics

Bluejay Diagnostics is a medical diagnostics company focused on rapid testing and blood-based diagnostic tools. Its business is centered on bringing point-of-care information to clinical settings rather than developing therapeutics.

Recent company news

BJDXBluejay Diagnostics2026-07-21 10:30 EST

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

BJDXBluejay Diagnostics2026-06-06 00:13 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 16:19 EST

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 10:30 EST

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

BJDXBluejay Diagnostics2026-05-07 20:01 EST

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Stock data

Close
1.15 USD
Market cap
4.49M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States